{
    "clinical_study": {
        "@rank": "92535", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Cyclophosphamide (Cytoxan)"
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this study is to assess the effects of cyclophosphamide (cytoxan)  in\n      the post transplant setting to prevent onset of acute graft-versus-host disease (GVHD). The\n      primary objective is to determine the incidence of grade II-IV acute GVHD following\n      Allogeneic (allo) Hematopoeitic Cell Transplant (HCT) using post-transplant cyclophosphamide\n      (cytoxan) for patients with human leukocyte antigen (HLA) matched unrelated (MUD) and\n      mismatched unrelated (MMUD) donors. Other objectives for this study will be the\n      determination of disease-free survival (DFS) and overall survival (OS) following allo HCT\n      and assess the safety of post-transplant cyclophosphamide (cytoxan) for MUD and MMUD\n      transplantation. Disease recurrence and time to recurrence in patients receiving\n      post-transplant cyclophosphamide compared to historical control without post-transplant\n      cyclophosphamide (cytoxan) will also be evaluated. Other objectives will be to determine the\n      time of onset, severity, responsiveness to treatment, organs involved of acute and chronic\n      GVHD as well as observation of Immune Reconstitution over time."
        }, 
        "brief_title": "Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Leukemia", 
            "Lymphoma", 
            "Myelodysplastic Syndrome", 
            "Myelofibrosis", 
            "Severe Aplastic Anemia", 
            "Allogeneic Transplant"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Primary Myelofibrosis", 
                "Anemia", 
                "Anemia, Aplastic", 
                "Leukemia", 
                "Lymphoma", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Disease Criteria: patients must meet diagnostic criteria of acute myeloid leukemia\n             (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic\n             lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL),\n             myelodysplastic syndrome (MDS), myelofibrosis, or severe aplastic anemia. Patients\n             will be allowed on study if they are deemed eligible for allo HCT regardless of\n             remission status.\n\n          -  Age Criteria: 19 to 65 years in age.\n\n          -  Organ Function Criteria: All organ function testing should be done within 28 days of\n             study registration.\n\n          -  Cardiac: Left ventricular ejection fraction (LVEF) \u2265 50% by MUGA (Multi Gated\n             Acquisition) scan or echocardiogram.\n\n          -  Pulmonary: FEV1 (Forced expiratory volume in 1 second) and FVC (Forced vital\n             capacity) \u2265 50% predicted, DLCO (diffusing capacity of the lung for carbon monoxide)\n             (corrected for hemoglobin) \u2265 50% of predicted.\n\n          -  Renal: The estimated creatinine clearance (CrCl) must be equal or greater than 60\n             mL/min/1.73 m2 as calculated by the Cockcroft-Gault Formula:\n\n        CrCl=(140-age) x weight(kg) x 0.85 (if female)/72 x serum creatinine (mg/dL)\n\n          -  Hepatic:\n\n               -  Serum bilirubin 1.5 upper limit of normal (ULN)\n\n               -  Aspartate transaminase (AST)/alanine transaminase (ALT) 2.5 ULN\n\n               -  Alkaline phosphatase 2.5 ULN\n\n          -  Performance status: Karnofsky \u2265 70%.,\n\n          -  Patient must be informed of the investigational nature of this study in accordance\n             with institutional and federal guidelines and have the ability to provide written\n             informed consent prior to initiation of any study-related procedures, and ability, in\n             the opinion of the principal investigator, to comply with all the requirements of the\n             study.\n\n          -  Patient has a suitable and willing HLA-8/8 matched or 6/8 mismatched (at one allele)\n             unrelated donor identified.\n\n        Exclusion Criteria:\n\n          -  Non-compliant to medications.\n\n          -  No appropriate caregivers identified.\n\n          -  HIV1 (Human Immunodeficiency Virus-1) or HIV2 positive\n\n          -  Uncontrolled medical or psychiatric disorders.\n\n          -  Uncontrolled infections, defined as positive blood cultures within 72 hours of study\n             entry, or evidence of progressive infection by imaging studies such as chest CT scan\n             within 14 days of registration.\n\n          -  Active central nervous system (CNS) leukemia.\n\n          -  Preceding allogeneic HSCT.\n\n          -  Pregnancy or Breastfeeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065154", 
            "org_study_id": "UAB 1286"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "intervention_name": "Cyclophosphamide", 
            "intervention_type": "Drug", 
            "other_name": "Cytoxan"
        }, 
        "intervention_browse": {
            "mesh_term": "Cyclophosphamide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "acute myeloid leukemia", 
            "AML", 
            "acute lymphoblastic leukemia", 
            "ALL", 
            "chronic myeloid leukemia", 
            "CML", 
            "chronic lymphocytic leukemia", 
            "CLL", 
            "non-Hodgkin lymphoma", 
            "NHL", 
            "Hodgkin lymphoma", 
            "HL", 
            "myelodysplastic syndrome", 
            "MDS", 
            "myelofibrosis", 
            "severe aplastic anemia"
        ], 
        "lastchanged_date": "February 14, 2014", 
        "location": {
            "contact": {
                "email": "liwilliams@uabmc.edu", 
                "last_name": "Lisa D Williams, RN", 
                "phone": "205-934-0066"
            }, 
            "contact_backup": {
                "email": "andrewdees@uabmc.edu", 
                "last_name": "Andrew T Dees", 
                "phone": "205-975-7665"
            }, 
            "facility": {
                "address": {
                    "city": "Birmingham", 
                    "country": "United States", 
                    "state": "Alabama", 
                    "zip": "35249"
                }, 
                "name": "UAB Bone Marrow Transplantation and Cellular Therapy Program"
            }, 
            "investigator": [
                {
                    "last_name": "Racquel D Innis-Shelton, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Shin Mineishi, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ayman A Saad, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Donna Salzman, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ruby F Meredith, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Lawrence S Lamb, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "William Donnellan, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)", 
        "overall_contact": {
            "last_name": "Lisa D Williams, RN", 
            "phone": "205-934-0066"
        }, 
        "overall_contact_backup": {
            "last_name": "Andrew T Dees", 
            "phone": "205-975-7665"
        }, 
        "overall_official": {
            "affiliation": "University of Alabama at Birmingham", 
            "last_name": "Racquel D Innis-Shelton, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Grade II-IV acute GVHD", 
            "safety_issue": "No", 
            "time_frame": "Assessed 1 time per week until 100 days post transplant. Then assessed 1 time per month until 1 year post transplant."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065154"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Alabama at Birmingham", 
            "investigator_full_name": "Racquel Innis-Shelton, MD", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "1 Year Post Transplant"
            }, 
            {
                "measure": "Disease-free Survival", 
                "safety_issue": "No", 
                "time_frame": "1 Year Post-transplant"
            }, 
            {
                "description": "Regimen Related Toxicity will be assessed for incidence within the first 100 days of transplant.", 
                "measure": "Regimen Related Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "100 Days Post Transplant"
            }, 
            {
                "description": "The rate and pattern of recovery of total lymphocytes, T cell subsets, B cells, and NK calls are evaluated by flow cytometry and  are quantified and reported as percentages of total cell counts.", 
                "measure": "Immune Reconstitution", 
                "safety_issue": "No", 
                "time_frame": "Days +30, +100, +18-, +365. And as clinically indicated."
            }, 
            {
                "description": "Relapse rate will be assessed at 2 years post-transplant", 
                "measure": "Relapse Rate", 
                "safety_issue": "No", 
                "time_frame": "2 years post-transplant"
            }
        ], 
        "source": "University of Alabama at Birmingham", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Racquel Innis-Shelton, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}